Health and Human Services Department, National Institutes of Health
The National Eye Institute, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Perpetual Biosciences, Inc., a company located in New York, NY.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services National Institutes of Health AGENCY: National Institutes of Health, HHS. ACTION: Notice. ( printed page 16206) SUMMARY: The National Eye Institute, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Perpetual Biosciences, Inc., a company located in New York, NY. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center, representing the National Eye Institute, on or before April 16, 2026 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Geoffrey E. Ravilious, Ph.D., NCI Technology Transfer Center, Telephone: 240-276-6391; Email: geoffrey.ravilious@nih.gov . SUPPLEMENTARY INFORMATION: Intellectual Property 1. United States Provisional Patent Application No. 63/430,251 filed December 5, 2022, entitled “PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION” [HHS Reference No. E-028-2023-0-US-01]; 2. International Patent Application PCT/US2024/064947 filed March 24, 2023, entitled “PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREA…
Citation: 91 FR 16205
